| Year |
Citation |
Score |
| 2023 |
Paraghamian SE, Qiu J, Hawkins GM, Zhao Z, Sun W, Fan Y, Zhang X, Suo H, Hao T, Prabhu VV, Allen JE, Zhou C, Bae-Jump V. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer. Cancer Biology & Therapy. 24: 2202104. PMID 37069726 DOI: 10.1080/15384047.2023.2202104 |
0.429 |
|
| 2022 |
Fan Y, Wang J, Fang Z, Pierce SR, West L, Staley A, Tucker K, Yin Y, Sun W, Kong W, Prabhu V, Allen JE, Zhou C, Bae-Jump VL. Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer. Frontiers in Oncology. 12: 789450. PMID 35372029 DOI: 10.3389/fonc.2022.789450 |
0.414 |
|
| 2022 |
Tucker K, Yin Y, Staley SA, Zhao Z, Fang Z, Fan Y, Zhang X, Suo H, Sun W, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer. American Journal of Cancer Research. 12: 521-536. PMID 35261784 |
0.458 |
|
| 2022 |
Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35022321 DOI: 10.1158/1078-0432.CCR-21-4030 |
0.357 |
|
| 2021 |
Staley A, Tucker K, Yin Y, Zhang X, Fan Y, Zhang Y, Fang Z, Sun W, Suo H, Zhao X, Zhao Z, Prabhu VV, Allen JE, Zhou C, Bae-Jump VL. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer. American Journal of Cancer Research. 11: 5374-5387. PMID 34873466 |
0.419 |
|
| 2021 |
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, Asad M, Martin ML, Sigouros M, Rowdo FM, Ackermann S, Capuano J, Bernheim J, Cheung C, Doane A, ... ... Allen JE, et al. Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors. Advanced Materials (Deerfield Beach, Fla.). e2100096. PMID 34676924 DOI: 10.1002/adma.202100096 |
0.341 |
|
| 2021 |
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, et al. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 12: 2231. PMID 34676056 DOI: 10.18632/oncotarget.28012 |
0.328 |
|
| 2021 |
He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34097975 DOI: 10.1016/j.radonc.2021.05.027 |
0.314 |
|
| 2021 |
Pierce SR, Fang Z, Yin Y, West L, Asher M, Hao T, Zhang X, Tucker K, Staley A, Fan Y, Sun W, Moore DT, Xu C, Tsai YH, Parker J, ... ... Allen JE, et al. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer. Journal of Experimental & Clinical Cancer Research : Cr. 40: 61. PMID 33557912 DOI: 10.1186/s13046-021-01842-9 |
0.397 |
|
| 2021 |
Bagheri-Yarmand R, Dadu R, Ye L, Jebaraj YS, Martinez JA, Ma J, Tarapore RS, Allen JE, Sherman SI, Williams MD, Gagel RF. ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Molecular Cancer Therapeutics. PMID 33536187 DOI: 10.1158/1535-7163.MCT-20-0386 |
0.398 |
|
| 2020 |
Zhang Y, Huang Y, Yin Y, Fan Y, Sun W, Zhao X, Tucker K, Staley A, Paraghamian S, Hawkins G, Prabhu V, Allen JE, Zhou C, Bae-Jump V. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer . Frontiers in Oncology. 10: 577141. PMID 33194693 DOI: 10.3389/fonc.2020.577141 |
0.353 |
|
| 2020 |
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, ... ... Allen JE, et al. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia (New York, N.Y.). 22: 725-744. PMID 33142238 DOI: 10.1016/j.neo.2020.09.005 |
0.625 |
|
| 2020 |
Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers. 12. PMID 32867127 DOI: 10.3390/Cancers12092436 |
0.471 |
|
| 2020 |
He Y, Li J, Koga T, Ma J, Dhawan S, Suzuki Y, Furnari F, Prabhu VV, Allen JE, Chen CC. Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors. Neuro-Oncology. PMID 32830856 DOI: 10.1093/Neuonc/Noaa188 |
0.356 |
|
| 2020 |
Theeler BJ, Jung J, Burton E, Gonzalez J, Leeper H, Wu J, Nduom E, Zaghloul K, Ray-Chaudhury A, Quezado M, Raffeld M, Allen JE, Prabhu VV, Stogniew M, Oster W, et al. A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2576 |
0.312 |
|
| 2020 |
He Y, Ma J, Dhawan S, Koga T, Furnari F, Prabhu VV, Allen JE, Chen CC. Epidermal growth factor receptor expression as a molecular determinant of glioblastoma response to the dopamine receptor D2 antagonist, ONC201. Journal of Clinical Oncology. 38: e14552-e14552. DOI: 10.1200/Jco.2020.38.15_Suppl.E14552 |
0.368 |
|
| 2020 |
Gardner SL, Koschmann CJ, Tarapore R, Allen JC, Zaky WT, Odia Y, Hall M, Daghistani D, Khatib Z, Aguilera D, MacDonald TJ, Fouladi M, McGovern SL, Kline C, Vitanza NA, ... ... Allen JE, et al. ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG. Journal of Clinical Oncology. 38: 3619-3619. DOI: 10.1200/Jco.2020.38.15_Suppl.3619 |
0.327 |
|
| 2020 |
Arrillaga-Romany I, Kurz SC, Tarapore R, Sumrall A, Butowski NA, Harrison RA, De Groot JF, Chi AS, Shonka NA, Umemura Y, Odia Y, Mehta MP, Nghiemphu PL, Cloughesy TF, Lu G, ... ... Allen JE, et al. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal of Clinical Oncology. 38: 3615-3615. DOI: 10.1200/Jco.2020.38.15_Suppl.3615 |
0.391 |
|
| 2020 |
Hawkins GM, Paraghamian SE, Fan Y, Sun W, Zhang X, Prabhu V, Allen JE, Zhou C, Bae-Jump VL. Abstract 5336: Olaparib potentiates the anti-proliferative and anti-metastatic effects of ONC206 in ovarian cancer cells Cancer Research. 80: 5336-5336. DOI: 10.1158/1538-7445.Am2020-5336 |
0.498 |
|
| 2020 |
Paraghamian SE, Hawkins GM, Sun W, Fan Y, Zhang X, Suo H, Prabhu VV, Allen JE, Zhou C, Bae-Jump V. Abstract 5314: A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway Cancer Research. 80: 5314-5314. DOI: 10.1158/1538-7445.Am2020-5314 |
0.532 |
|
| 2020 |
Morrow S, Prabhu VV, Allen JE, Oster W. Abstract 3173: Predictive biomarker evaluation for the anti-cancer imipridone ONC201 Clinical Trials. DOI: 10.1158/1538-7445.Am2020-3173 |
0.35 |
|
| 2019 |
Madhukar NS, Khade PK, Huang L, Gayvert K, Galletti G, Stogniew M, Allen JE, Giannakakou P, Elemento O. A Bayesian machine learning approach for drug target identification using diverse data types. Nature Communications. 10: 5221. PMID 31745082 DOI: 10.1038/S41467-019-12928-6 |
0.33 |
|
| 2019 |
Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology. PMID 31702782 DOI: 10.1093/Neuonc/Noz164 |
0.308 |
|
| 2019 |
Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, ... Allen JE, et al. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. PMID 31127149 DOI: 10.1038/S41375-019-0491-Z |
0.454 |
|
| 2019 |
Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, ... ... Allen JE, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Journal For Immunotherapy of Cancer. 7: 136. PMID 31118108 DOI: 10.1186/S40425-019-0599-8 |
0.508 |
|
| 2019 |
Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. Journal of Neurosurgery. Pediatrics. 1-7. PMID 30952114 DOI: 10.3171/2019.2.Peds18480 |
0.376 |
|
| 2019 |
Arrillaga I, Kurz S, Sumrall A, Butowski NA, Harrison RA, De Groot JF, Shonka NA, Lieberman FS, Odia Y, Tarapore R, Merdinger K, Allen JE, Oster W, Mehta MP, Cloughesy TF, et al. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal of Clinical Oncology. 37: 3005-3005. DOI: 10.1200/Jco.2019.37.15_Suppl.3005 |
0.341 |
|
| 2019 |
Gardner SL, Allen JC, Zaky WT, Odia Y, Daghistani D, Khatib Z, Koschmann CJ, Aguilera D, MacDonald TJ, Chi AS, Tarapore R, Merdinger K, Oster W, Allen JE, Khatua S. ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma. Journal of Clinical Oncology. 37: 10046-10046. DOI: 10.1200/Jco.2019.37.15_Suppl.10046 |
0.304 |
|
| 2019 |
Prabhu VV, Kawakibi AR, Madhukar N, Garnett MJ, McDermott U, Benes CH, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker JB, Doranz BJ, Rusert J, Wechsler-Reya R, Elemento O, ... ... Allen JE, et al. Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology Cancer Research. 79: 3877-3877. DOI: 10.1158/1538-7445.Sabcs18-3877 |
0.43 |
|
| 2019 |
Allegakoen DV, Tarapore RS, Allen JE, Sabnis AJ, Bivona TG. Abstract 2664: Differential activation of the integrated stress response correlates with anti-tumor activity of imipridones ONC201 and ONC206 in pediatric sarcomas Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2664 |
0.339 |
|
| 2019 |
Tarapore RS, Jhawar S, Stein M, Zloza A, Mueller S, Zhang J, Amoroso F, Mills I, Oster W, Allen J. Abstract 249: Combination of ONC201 with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-249 |
0.371 |
|
| 2019 |
Prabhu VV, Kawakibi AR, Madhukar NS, Anantharaman L, Deacon S, Charter NS, Garnett MJ, McDermott U, Benes CH, Oster W, Elemento O, Stogniew M, Allen JE. Abstract 2749: Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules Cancer Research. 79: 2749-2749. DOI: 10.1158/1538-7445.Am2019-2749 |
0.489 |
|
| 2019 |
Bagheri-Yarmand R, Li L, Tarapore R, Allen JE, Sherman SI, Gagel RF. Abstract 1286: ONC201 inhibits RET and IGFBP2 signaling through ATF4 mediated- Integrated stress response in medullary thyroid cancer Cancer Research. 79: 1286-1286. DOI: 10.1158/1538-7445.Am2019-1286 |
0.51 |
|
| 2019 |
Sharma A, Lai Y, Kennis B, Sridharan S, Dobson T, Swaminathan J, Khatua S, Sandberg D, Allen J, Tarapore R, Gopalakrishnan V, Zaky W. PDTM-25. STUDY OF ONC201 IN PRE-CLINICAL MODELS OF DIPG Neuro-Oncology. 21: vi192-vi192. DOI: 10.1093/Neuonc/Noz175.801 |
0.495 |
|
| 2019 |
Rahman Kawakibi A, Gardner S, Chi A, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, DeGroot J, Mehta M, Odia Y, Hall M, ... ... Allen J, et al. PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA Neuro-Oncology. 21: vi186-vi186. DOI: 10.1093/Neuonc/Noz175.773 |
0.327 |
|
| 2019 |
Prabhu V, Rahman Kawakibi A, Madhukar N, Garnett M, McDermott U, Benes C, Wechsler-Reya R, Elemento O, Stogniew M, Oster W, DeMorrow S, Allen J. EXTH-71. IND-ENABLING CHARACTERIZATION OF ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR NEURO-ONCOLOGY Neuro-Oncology. 21: vi97-vi97. DOI: 10.1093/Neuonc/Noz175.401 |
0.39 |
|
| 2019 |
Benjamin Free R, Cuoco C, Prabhu V, Willette B, Day M, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Stogniew M, Robert Lane J, ... ... Allen J, et al. EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 21: vi89-vi89. DOI: 10.1093/Neuonc/Noz175.365 |
0.416 |
|
| 2019 |
Prabhu V, Cuoco C, Jung J, Rahman Kawakibi A, Willette B, Day M, Anantharaman L, Charter N, Rucker J, Doranz B, Oster W, Stogniew M, Gilbert M, Benjamin Free R, Sibley D, ... Allen J, et al. DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY Neuro-Oncology. 21: vi67-vi67. DOI: 10.1093/Neuonc/Noz175.271 |
0.409 |
|
| 2019 |
Arrillaga-Romany I, Kurz S, Sumrall A, Butowski N, Harrison R, DeGroot J, Chi A, Sulman E, Shonka N, Umemura Y, Odia Y, Mehta M, Iwamoto F, Leia Nghiemphu P, Cloughesy T, ... ... Allen J, et al. ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA Neuro-Oncology. 21: vi20-vi21. DOI: 10.1093/Neuonc/Noz175.077 |
0.339 |
|
| 2018 |
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty FC, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, ... ... Allen JE, et al. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30559168 DOI: 10.1158/1078-0432.Ccr-18-2572 |
0.514 |
|
| 2018 |
Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TT, Kleiner G, Sanchez-Quintero M, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD. Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037819 DOI: 10.1158/1078-0432.Ccr-18-1040 |
0.339 |
|
| 2018 |
Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. British Journal of Haematology. PMID 29740811 DOI: 10.1111/Bjh.15271 |
0.328 |
|
| 2018 |
Arrillaga I, Odia Y, Allen JE, Prabhu VV, Tarapore R, Oster W, Mehta MP, Wen PY, Batchelor T. Intratumoral activity of ONC201 in adult recurrent glioblastoma patients. Journal of Clinical Oncology. 36: e14034-e14034. DOI: 10.1200/Jco.2018.36.15_Suppl.E14034 |
0.428 |
|
| 2018 |
Stein MN, Malhotra J, Malhotra U, Silk AW, Chan N, Rodriguez-Rodriguez L, Aisner J, Aiken R, Newman J, Sadimin E, Saunders T, Frankel M, Kareddula A, El-Deiry WS, Tarapore R, ... Allen JE, et al. Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Journal of Clinical Oncology. 36: 2595-2595. DOI: 10.1200/Jco.2018.36.15_Suppl.2595 |
0.56 |
|
| 2018 |
Chi AS, Gardner SL, Arrillaga I, Wen PY, Batchelor T, Hall MD, Odia Y, Zaky WT, Khatua S, Shonka NA, Khatib Z, Tarapore R, Schalop L, Allen JE, Oster W, et al. Integrated clinical experience with ONC201 in H3 K27M glioma. Journal of Clinical Oncology. 36: 2059-2059. DOI: 10.1200/Jco.2018.36.15_Suppl.2059 |
0.323 |
|
| 2018 |
Su Y, Li X, Edwards H, Polin L, Kushner J, Dzinic SH, Hege K, Fukuda Y, Schuetz JD, Allen JE, Stogniew M, Prabhu VV, Taub JW, Lin H, Ge Y. Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia Blood. 132: 3936-3936. DOI: 10.1182/Blood-2018-99-116997 |
0.44 |
|
| 2018 |
Amoroso F, Pickard A, Glass K, Tarapore R, Allen JE, Mills IG. Abstract 839: Treatment and signaling contexts for the application of the imipridone ONC201 to prostate cancer cells Cancer Research. 78: 839-839. DOI: 10.1158/1538-7445.Am2018-839 |
0.437 |
|
| 2018 |
Tarapore RS, Stein MN, Zloza A, Rodriguez L, Newman J, Cheeson C, Stogniew M, Oster W, Allen JE. Abstract 5568: Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients Cancer Research. 78: 5568-5568. DOI: 10.1158/1538-7445.Am2018-5568 |
0.499 |
|
| 2018 |
Nii T, Ishizawa J, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Kojima K, Garnett M, McDermott U, Benes C, Charter N, Deacon S, Elemento O, ... Allen J, et al. Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132 Cancer Research. 78: 4957-4957. DOI: 10.1158/1538-7445.Am2018-4957 |
0.519 |
|
| 2018 |
Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, VanEngelenburg A, Rucker J, Doranz B, Elemento O, Oster W, Stogniew M, Allen J. Abstract 4874: Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206 Cancer Research. 78: 4874-4874. DOI: 10.1158/1538-7445.Am2018-4874 |
0.495 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry WS, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Deacon S, Charter N, Free RB, Oster W, ... ... Allen JE, et al. Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 Cancer Research. 78: 3857-3857. DOI: 10.1158/1538-7445.Am2018-3857 |
0.546 |
|
| 2018 |
Javadi A, Forsythe N, Refaat A, Weir J, Khawaja H, Waugh D, Tarapore R, Allen JE, Johnston P, Schaeybroeck SV. Abstract 3448: Targeting the dopamine receptor 2 in BRAF mutant colorectal cancer Cancer Research. 78: 3448-3448. DOI: 10.1158/1538-7445.Am2018-3448 |
0.499 |
|
| 2018 |
Jhawar SR, Schiff D, Wu H, Thandoni A, Hassan S, Allen J, Stogniew M, Tarapore R, Oster W, Stein M, Silk AW, Goyal S, Haffty BG, Zloza A. Abstract 2765: Combination ONC201 and radiation therapy in the treatment of breast cancer Immunology. DOI: 10.1158/1538-7445.Am2018-2765 |
0.317 |
|
| 2018 |
Madhukar NS, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B130 |
0.396 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry W, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Zloza A, Benes C, Arrillaga I, Oster W, Allen JE. Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A060 |
0.617 |
|
| 2018 |
Cuoco CA, Free RB, Willette BK, Day MM, Lane JR, Allen JE, Sibley DR. Characterization of the novel anti-cancer therapeutic ONC201 and related analogs as non-competitive antagonists of the D2 dopamine receptor The Faseb Journal. 32. DOI: 10.1096/Fasebj.2018.32.1_Supplement.827.10 |
0.434 |
|
| 2018 |
Gardner S, Suarez F, Stafford JM, S. Tarapore R, Merdinger K, Oster W, Allen J, S. Chi A, Fuller-Becker H, Yaffe A, C. Allen J. PDCT-06. PHASE 1 STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH H3 K27M-MUTANT HIGH GRADE GLIOMA OR NEWLY DIAGNOSED DIPG Neuro-Oncology. 20: vi201-vi201. DOI: 10.1093/Neuonc/Noy148.836 |
0.333 |
|
| 2018 |
Jung J, Dowdy T, Tabouret E, Reynolds B, Allen J, Larion M, Gilbert M, Park D. EXTH-58. ONC206, AN IMIPRIDONE FAMILY MEMBER, SUPPRESSES GLIOBLASTOMA CELLS VIA BLOCKING CANCER STEMNESS PATHWAYS Neuro-Oncology. 20: vi97-vi97. DOI: 10.1093/Neuonc/Noy148.406 |
0.383 |
|
| 2018 |
Li J, Ma J, He Y, Vijay Prabhu V, Allen J, Chen C. EXTH-26. MOLECULAR DETERMINANT OF CLINICAL RESPONSE TO ONC201, AN INHIBITOR OF DOPAMINE RECEPTOR 2 (DRD2) SIGNALING, IN GLIOBLASTOMA PATIENT Neuro-Oncology. 20: vi90-vi90. DOI: 10.1093/Neuonc/Noy148.375 |
0.311 |
|
| 2018 |
Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker J, Doranz B, Rusert J, Wechsler-Reya R, Elemento O, ... ... Allen J, et al. EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION Neuro-Oncology. 20: vi88-vi88. DOI: 10.1093/Neuonc/Noy148.366 |
0.341 |
|
| 2018 |
Vijay Prabhu V, Madhukar N, Gilvary C, Kline CLB, Tarapore R, El-Deiry W, Doherty F, VanEngelenburg A, Durrant J, Benes C, Oster W, Elemento O, Allen J. DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201 Neuro-Oncology. 20: vi77-vi78. DOI: 10.1093/Neuonc/Noy148.317 |
0.41 |
|
| 2018 |
Tarapore R, Jhawar S, Stein M, Haffty B, Zloza A, Mueller S, Zhang J, Amoroso F, Mills I, Oster W, Allen J. DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS Neuro-Oncology. 20: vi72-vi72. DOI: 10.1093/Neuonc/Noy148.295 |
0.488 |
|
| 2018 |
Arrillaga-Romany I, Odia Y, Allen J, Prabhu VV, Tarapore R, Costa DV, Shah N, Cukierman E, Oster W, Mehta M, Wen P, Batchelor T. Actr-33. Tumor Tissue Penetration And Pharmacodynamics Of Onc201 In Adult Recurrent Glioblastoma Patients Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.066 |
0.316 |
|
| 2018 |
Suarez F, Stafford JM, Tarapore R, Oster W, Allen JE, Chi AS, Gardner S. DIPG-54. TREATMENT OF A PEDIATRIC PATIENT WITH AN H3.3 K27M MUTANT DIPG WITH ONC201, A SELECTIVE DRD2 ANTAGONIST Neuro-Oncology. 20: i60-i60. DOI: 10.1093/Neuonc/Noy059.147 |
0.351 |
|
| 2017 |
Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia (New York, N.Y.). 20: 80-91. PMID 29216597 DOI: 10.1016/J.Neo.2017.10.002 |
0.581 |
|
| 2017 |
Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, ... ... Allen JE, et al. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle (Georgetown, Tex.). 1-29. PMID 29157092 DOI: 10.1080/15384101.2017.1403689 |
0.581 |
|
| 2017 |
Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 8: 79298-79304. PMID 29108308 DOI: 10.18632/Oncotarget.17837 |
0.408 |
|
| 2017 |
Ni X, Zhang X, Hu CH, Langridge T, Tarapore RS, Allen JE, Oster W, Duvic M. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways. Oncotarget. 8: 61761-61776. PMID 28977902 DOI: 10.18632/Oncotarget.18688 |
0.464 |
|
| 2017 |
Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia (New York, N.Y.). 19: 772-780. PMID 28863346 DOI: 10.1016/J.Neo.2017.07.009 |
0.445 |
|
| 2017 |
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. Plos One. 12: e0180541. PMID 28767654 DOI: 10.1371/Journal.Pone.0180541 |
0.622 |
|
| 2017 |
Ni X, Zhang X, Hu CH, Langridge T, Tarapore RS, Allen JE, Oster W, Duvic M. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways. Oncotarget. PMID 28700333 DOI: 10.18632/oncotarget.18688 |
0.36 |
|
| 2017 |
Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle (Georgetown, Tex.). 0. PMID 28489985 DOI: 10.1080/15384101.2017.1325046 |
0.656 |
|
| 2017 |
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez-Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, ... ... Allen J, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28331050 DOI: 10.1158/1078-0432.Ccr-16-2658 |
0.551 |
|
| 2017 |
Talekar MK, Hall J, Wertheim GB, Martinez D, Allen JE, Grupp SA. Effect of ONC201 and bortezomib on apoptosis in non-Hodgkin's lymphoma (NHL) xenografts. Journal of Clinical Oncology. 35: e19016-e19016. DOI: 10.1200/Jco.2017.35.15_Suppl.E19016 |
0.451 |
|
| 2017 |
Rodriguez-Rodriguez L, Mehnert JM, Silk AW, Chan N, Malhotra J, Aisner J, Saunders T, Yu B, Dickerson S, Tarapore R, Allen JE, Stogniew M, Oster W, Kaufman H, Haffty BG, et al. Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). Journal of Clinical Oncology. 35: 5592-5592. DOI: 10.1200/Jco.2017.35.15_Suppl.5592 |
0.399 |
|
| 2017 |
Stein MN, Chan N, Silk AW, Malhotra J, Aisner J, Aiken R, Zloza A, El-Deiry WS, Newman J, Chesson C, Tarapore R, Allen JE, Oster W, Saunders T, Yu B, et al. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. Journal of Clinical Oncology. 35: 2586-2586. DOI: 10.1200/Jco.2017.35.15_Suppl.2586 |
0.58 |
|
| 2017 |
Amoroso F, Pickard A, McNaney A, Tarapore R, Allen JE, Mills IG. Abstract 5195: Modulating the UPR using the impridone ONC201 to change the impact of radiation on prostate cancer cells Cancer Research. 77: 5195-5195. DOI: 10.1158/1538-7445.Am2017-5195 |
0.421 |
|
| 2017 |
Prabhu VV, Madhukar N, Wagner J, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, VanEngelenburg A, Elemento O, El-Deiry W, Stogniew M, Oster W, Allen J. Abstract 4147A: Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-4147A |
0.612 |
|
| 2017 |
Wagner J, Kline CL, Olson G, Nallaganchu B, Pottorf R, Prabhu V, Stogniew M, Allen J, El-Deiry W. Abstract 3245: Preclinical evaluation of the imipridone family of small molecules, including analogues of clinical-stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 Cancer Research. 77: 3245-3245. DOI: 10.1158/1538-7445.Am2017-3245 |
0.636 |
|
| 2017 |
Madhukar N, Prabhu VV, Dardenne E, Doherty F, VanEngelenburg A, Tarapore R, Garnett M, McDermott U, Benes C, Oster W, El-Deiry W, Stein M, Rickman D, Allen J, Elemento O. Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway Cancer Research. 77: 2792-2792. DOI: 10.1158/1538-7445.Am2017-2792 |
0.64 |
|
| 2017 |
Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, Oster W, Andreeff M, Elemento O, Stogniew M, Allen J. Abstract 1155: Potent anti-cancer effects of selective GPR132/G2A agonist imipridone ONC212 in leukemia and lymphoma Cancer Research. 77: 1155-1155. DOI: 10.1158/1538-7445.Am2017-1155 |
0.528 |
|
| 2017 |
Tu Y, He J, Liu H, Davis RE, Orlowski RZ, Prabhu VV, Allen J, Yang J. Abstract 1066: Imipridone ONC201 efficacy in refractory multiple myeloma via Erk1/2 inhibition and pro-apoptotic Bim upregulation: single agent and combinatorial approaches Cancer Research. 77: 1066-1066. DOI: 10.1158/1538-7445.Am2017-1066 |
0.506 |
|
| 2017 |
Madhukar N, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Tarapore R, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 19: vi81-vi82. DOI: 10.1093/Neuonc/Nox168.335 |
0.401 |
|
| 2017 |
Chi AS, Stafford JM, Sen N, Possemato R, Placantonakis D, Hidalgo ET, Harter D, Wisoff J, Golfinos J, Arrillaga-Romany I, Batchelor T, Wen P, Wakimoto H, Cahill D, Allen JE, et al. EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2 Neuro-Oncology. 19: vi81-vi81. DOI: 10.1093/Neuonc/Nox168.334 |
0.334 |
|
| 2017 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore RS, El-Deiry W, Elemento O, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Arrillaga-Romany I, Oster W, Allen JE. DDIS-08. THE SMALL MOLECULE IMIPRIDONE ONC201 IS ACTIVE IN GLIOBLASTOMA WITH DRD2 PATHWAY DYSREGULATION Neuro-Oncology. 19: vi60-vi60. DOI: 10.1093/Neuonc/Nox168.244 |
0.454 |
|
| 2016 |
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814 |
0.614 |
|
| 2016 |
Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Science Signaling. 9: ra18. PMID 26884600 DOI: 10.1126/Scisignal.Aac4374 |
0.595 |
|
| 2016 |
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9: ra17. PMID 26884599 DOI: 10.1126/Scisignal.Aac4380 |
0.466 |
|
| 2016 |
Allen JE, Crowder RN, El-Deiry WS. Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 11: e0149365. PMID 26863230 DOI: 10.1371/journal.pone.0149365 |
0.544 |
|
| 2016 |
Prabhu VV, Hong B, Allen JE, Zhang S, Lulla A, Dicker DT, El-Deiry WS. Small molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-Jun-mediated ΔNp73 inhibition and p73 activation. Cancer Research. PMID 26759239 DOI: 10.1158/0008-5472.Can-14-2430 |
0.579 |
|
| 2016 |
Lee HJ, Andreeff M, Benes C, Allen JE, Schalop L, Oster W, Wang M. First-in-class small molecule ONC201 in b-cell malignancies. Journal of Clinical Oncology. 34: TPS7581-TPS7581. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps7581 |
0.375 |
|
| 2016 |
Wagner J, Olson G, Nallaganchu BR, Pottorf R, Stogniew M, Schalop L, Oster W, Garnett M, McDermott U, Benes C, Tarapore R, Allen JE, El-Deiry WS. Structure-activity relationships (SAR) and mechanistic analysis of clinical-stage anti-cancer small molecule ONC201 analogues. Journal of Clinical Oncology. 34: e23161-e23161. DOI: 10.1200/Jco.2016.34.15_Suppl.E23161 |
0.597 |
|
| 2016 |
Stein MN, Kaufman H, Benes C, Stogniew M, Oster W, Allen JE, Haffty BG, Bertino JR. Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: e16514-e16514. DOI: 10.1200/Jco.2016.34.15_Suppl.E16514 |
0.363 |
|
| 2016 |
Baumeister MD, Wagner J, Prabhu VV, Kline CLB, Allen JE, Dicker DT, El-Deiry WS. Preclinical activity of new investigational drug ONC201 in triple-negative and non-triple negative and BRCA1-deficient breast cancer cells. Journal of Clinical Oncology. 34: e12564-e12564. DOI: 10.1200/Jco.2016.34.15_Suppl.E12564 |
0.624 |
|
| 2016 |
Stein MN, Chan N, Silk AW, Fang B, Kaufman H, Haffty BG, Saunders T, Najmi S, Zheng L, Stogniew M, Allen JE, Oster W, Bertino JR, Mehnert JM. First-in-human trial of ONC201 in patients with refractory solid tumors. Journal of Clinical Oncology. 34: 2514-2514. DOI: 10.1200/Jco.2016.34.15_Suppl.2514 |
0.386 |
|
| 2016 |
Prabhu VV, Tarapore RS, Garnett MJ, McDermott U, Benes CH, Wagner JM, El-Deiry WS, Stogniew M, Oster W, Allen JE. Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds Blood. 128: 5133-5133. DOI: 10.1182/Blood.V128.22.5133.5133 |
0.623 |
|
| 2016 |
Tu Y, He J, Liu H, Davis RE, Orlowski RZ, Allen JE, Yang J. ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma Blood. 128: 4476-4476. DOI: 10.1182/Blood.V128.22.4476.4476 |
0.502 |
|
| 2016 |
Nii T, Ishizawa J, Zhao R, Zeng J, Chachad D, Kojima K, Konopleva M, Davis RE, Allen JE, Stogniew M, Andreeff M. ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies Blood. 128: 4059-4059. DOI: 10.1182/Blood.V128.22.4059.4059 |
0.512 |
|
| 2016 |
Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias Blood. 128: 3997-3997. DOI: 10.1182/Blood.V128.22.3997.3997 |
0.369 |
|
| 2016 |
Prabhu VV, Lulla A, Kline CL, Van den Heuvel PJ, Talekar MK, Wagner JM, Tarapore RS, Dicker DT, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Oster W, Allen JE, et al. Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma Blood. 128: 2759-2759. DOI: 10.1182/Blood.V128.22.2759.2759 |
0.621 |
|
| 2016 |
Madhukar NS, Elemento O, Benes CH, Garnett MJ, Stein M, Bertino JR, Kaufman HL, Arrillaga-Romany I, Batchelor TT, Schalop L, Oster W, Stogniew M, Andreeff M, El-Deiry WS, Allen JE. Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-209 |
0.551 |
|
| 2016 |
Lev A, Wagner J, Dicker DT, Stogniew M, Allen JE, Schalop L, Oster W, Olson GL, El-Deiry WS. Abstract 4826: ONC212 exhibits increased cytotoxicity relative to ONC201 in a subset of human pancreatic cancer cell lines Cancer Research. 76: 4826-4826. DOI: 10.1158/1538-7445.Am2016-4826 |
0.636 |
|
| 2016 |
Prabhu VV, Allen JE, Zhao D, Lulla AR, Kline CLB, Heuvel APJvd, Lev A, Batchelor TT, Dicker DT, Chi AS, El-Deiry WS. Abstract 2497: ONC201 targets cancer stem cells in colorectal, prostate and glioblastoma multiforme tumors via modulation of stem cell-related gene expression Cancer Research. 76: 2497-2497. DOI: 10.1158/1538-7445.Am2016-2497 |
0.618 |
|
| 2016 |
Tarapore R, Garnett M, McDermott U, Benes C, Allen J. Abstract 1236: ONC201 sensitivity profiling indicates pronounced sensitivity in lymphoid, prostate, colon and brain tumors Cancer Research. 76: 1236-1236. DOI: 10.1158/1538-7445.Am2016-1236 |
0.511 |
|
| 2015 |
Allen JE, Crowder R, El-Deiry WS. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 10: e0143082. PMID 26580220 DOI: 10.1371/Journal.Pone.0143082 |
0.609 |
|
| 2015 |
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (Georgetown, Tex.). 1-7. PMID 26030065 DOI: 10.1080/15384101.2015.1054086 |
0.598 |
|
| 2015 |
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion On Therapeutic Targets. 1-15. PMID 26004811 DOI: 10.1517/14728222.2015.1049838 |
0.588 |
|
| 2015 |
Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14: 99. PMID 25927855 DOI: 10.1186/S12943-015-0346-9 |
0.715 |
|
| 2015 |
Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biology & Therapy. 16: 709-13. PMID 25806877 DOI: 10.1080/15384047.2015.1030555 |
0.585 |
|
| 2015 |
Kaifi JT, Kunkel M, Dicker DT, Joude J, Allen JE, Das A, Zhu J, Yang Z, Sarwani NE, Li G, Staveley-O'Carroll KF, El-Deiry WS. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biology & Therapy. 16: 690-8. PMID 25785486 DOI: 10.1080/15384047.2015.1026508 |
0.571 |
|
| 2015 |
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Research. 75: 1423-32. PMID 25712124 DOI: 10.1158/0008-5472.Can-13-3451 |
0.641 |
|
| 2015 |
Ford CA, Petrova S, Pound JD, Voss JJ, Melville L, Paterson M, Farnworth SL, Gallimore AM, Cuff S, Wheadon H, Dobbin E, Ogden CA, Dumitriu IE, Dunbar DR, Murray PG, ... ... Allen JE, et al. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology : Cb. 25: 577-88. PMID 25702581 DOI: 10.1016/J.Cub.2014.12.059 |
0.392 |
|
| 2015 |
McKee CM, Ding Y, Zhou J, Li C, Huang L, Xin X, He J, Allen JE, El-Deiry WS, Cao Y, Muschel RJ, Xu D. Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. Oncotarget. 6: 3784-96. PMID 25686839 DOI: 10.18632/Oncotarget.2921 |
0.567 |
|
| 2015 |
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75: 1668-74. PMID 25681273 DOI: 10.1158/0008-5472.Can-14-2356 |
0.597 |
|
| 2015 |
Stein MN, Mayer TM, Moss RA, Silk AW, Chan N, Haffty BG, DiPaola RS, Beckett Y, Bentlyewski E, Zheng L, Fang B, Allen J, Mehnert JM. First-in-human dose escalation study of oral ONC201 in advanced solid tumors. Journal of Clinical Oncology. 33: TPS2623-TPS2623. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps2623 |
0.478 |
|
| 2015 |
Khan N, Zhou L, Babar J, Allen J, Fisher RI, Eldeiry WS. ABT199 and ONC201 in Diffuse Large B Cell Lymphoma Cell Lines Blood. 126: 5129-5129. DOI: 10.1182/Blood.V126.23.5129.5129 |
0.481 |
|
| 2015 |
Allen J, Tarapore R, Garnett MJ, Benes C. ONC201 Exhibits Mutation-Independent Efficacy with Superior Potency in Non-Hodgkin Lymphoma and Multiple Myeloma Blood. 126: 3873-3873. DOI: 10.1182/Blood.V126.23.3873.3873 |
0.523 |
|
| 2015 |
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski RZ, et al. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response Blood. 126: 2051-2051. DOI: 10.1182/Blood.V126.23.2051.2051 |
0.458 |
|
| 2015 |
Kline CL, Heuvel Pvd, Allen JE, Dicker DT, El-Deiry WS. Abstract 674: Early integrated stress response induction of ATF4 is required for the anticancer effects of the dual Akt/ERK inhibitor and TRAIL pathway inducer ONC201/TIC10 Cancer Research. 75: 674-674. DOI: 10.1158/1538-7445.Am2015-674 |
0.606 |
|
| 2015 |
Talekar MK, Dicker D, Allen J, El-Deiry W. Abstract 5387: ONC201/TIC10 is effective as a monoagent and synergizes with chemotherapy to induce cell death in non-Hodgkin's lymphoma Cancer Research. 75: 5387-5387. DOI: 10.1158/1538-7445.Am2015-5387 |
0.627 |
|
| 2015 |
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. Abstract 4499: Cytotoxicity, biochemical activity, and structural analysis of ONC201 and comparisons to a biologically inactive isomer Cancer Research. 75: 4499-4499. DOI: 10.1158/1538-7445.Am2015-4499 |
0.545 |
|
| 2015 |
Allen JE, El-Deiry WS. Abstract 4479: ONC201 is non-toxic at efficacious doses in vitro and in vivo Cancer Research. 75: 4479-4479. DOI: 10.1158/1538-7445.Am2015-4479 |
0.586 |
|
| 2015 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M, Garnett M, Benes C. Abstract 4475: In vitro efficacy profiling of ONC201 in cancer cells reveals sensitivity pattern that is consistent with ER stress response Cancer Research. 75: 4475-4475. DOI: 10.1158/1538-7445.Am2015-4475 |
0.616 |
|
| 2015 |
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Abstract 4241: ONC201/TIC10 targets colorectal cancer stem cells and bulk tumor cells via an Akt-Foxo3a-TRAIL-dependent mechanism Cancer Research. 75: 4241-4241. DOI: 10.1158/1538-7445.Am2015-4241 |
0.652 |
|
| 2015 |
Kline CL, Lulla AR, Dicker D, Allen JE, El-Deiry W. Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis Cancer Research. 75: 2942-2942. DOI: 10.1158/1538-7445.Am2015-2942 |
0.58 |
|
| 2015 |
Prabhu VV, Zhang S, Hong B, Allen JE, Lulla A, Dicker DT, El-Deiry WS. Abstract 1215: Small molecule Prodigiosin-mediated p53 pathway restoration and inhibition of self-renewal in colorectal cancer involves c-Jun-mediated ΔNp73 inhibition and p73 activation Cancer Research. 75: 1215-1215. DOI: 10.1158/1538-7445.Am2015-1215 |
0.576 |
|
| 2015 |
Baumeister MD, Wagner J, Kline CLB, Allen JE, Dicker DT, El-Deiry WS. Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-A16 |
0.617 |
|
| 2015 |
Stein MN, Moss R, Mayer T, Silk AW, Chan N, Zheng L, Beckett Y, Tenpenny N, Bentlyewski E, DiPaola R, Tarapore R, Allen J, Mehnert J. Abstract C137: First-in-human dose escalation study of oral ONC201 in advanced solid tumors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C137 |
0.448 |
|
| 2014 |
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 5: 12728-37. PMID 25587031 DOI: 10.18632/Oncotarget.2890 |
0.528 |
|
| 2014 |
Patel AS, Allen JE, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. Oncology Letters. 7: 2110-2112. PMID 24932298 DOI: 10.3892/Ol.2014.1993 |
0.535 |
|
| 2014 |
Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Research. 74: 2385-90. PMID 24614081 DOI: 10.1158/0008-5472.Can-13-2660 |
0.561 |
|
| 2014 |
Zhang L, Ren X, Cheng Y, Liu X, Allen JE, Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, Webb BS, Connor J, Liu CG, Lu Z, El-Deiry WS, et al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biology & Therapy. 15: 602-11. PMID 24557012 DOI: 10.4161/Cbt.28158 |
0.545 |
|
| 2014 |
Sinha I, Allen JE, Pinto JT, Sinha R. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Medicine. 3: 252-64. PMID 24515947 DOI: 10.1002/Cam4.198 |
0.425 |
|
| 2014 |
Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 5: 1753-60. PMID 24334302 DOI: 10.18632/Oncotarget.1524 |
0.474 |
|
| 2014 |
Zhao D, Sundaram S, Wakimoto H, Curry WT, Cahill DP, Batchelor T, Flaherty K, Allen J, Chi AS. ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells. Journal of Clinical Oncology. 32: e13022-e13022. DOI: 10.1200/Jco.2014.32.15_Suppl.E13022 |
0.503 |
|
| 2014 |
Prabhu VV, Lulla AR, Wagner JM, Hernandez-Borrero LJ, Talekar MK, Kline CL, Dicker DT, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins Blood. 124: 5237-5237. DOI: 10.1182/Blood.V124.21.5237.5237 |
0.624 |
|
| 2014 |
Wagner JM, Prabhu VV, Kline LL, Lulla AR, Hernandez-Borrero LJ, Pu JJ, Dicker DT, Barth BM, Claxton DF, Allen JE, El-Deiry WS. Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells Blood. 124: 5233-5233. DOI: 10.1182/Blood.V124.21.5233.5233 |
0.596 |
|
| 2014 |
Lulla AR, Kline CLB, Hernandez-Borrero LJ, Prabhu VV, Wagner JM, Dicker DT, Dolloff NG, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Caspase-Dependent Anti-Tumor Effects of ONC201/TIC10 on Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) Blood. 124: 5224-5224. DOI: 10.1182/Blood.V124.21.5224.5224 |
0.615 |
|
| 2014 |
Prabhu VV, Ishizawa J, Zhao D, Allen JE, Batchelor TT, Chi AS, Andreeff M, El-Deiry WS. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples Blood. 124: 5219-5219. DOI: 10.1182/Blood.V124.21.5219.5219 |
0.618 |
|
| 2014 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies Blood. 124: 4812-4812. DOI: 10.1182/Blood.V124.21.4812.4812 |
0.599 |
|
| 2014 |
Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, Allen JE, Neelapu SS, McDonnell TJ, Miranda RN, Kwak LW, et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition Blood. 124: 3122-3122. DOI: 10.1182/Blood.V124.21.3122.3122 |
0.453 |
|
| 2014 |
Prabhu VV, Hong B, Allen JE, Zhang S, Dicker DT, El-Deiry WS. Abstract 202: p53 pathway restoring small molecule Prodigiosin targets chemotherapy-resistant colorectal cancer stem cells in vitro and in vivo via p73 activation Cancer Research. 74: 202-202. DOI: 10.1158/1538-7445.Am2014-202 |
0.612 |
|
| 2013 |
Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. Plos One. 8: e75414. PMID 24086526 DOI: 10.1371/Journal.Pone.0075414 |
0.575 |
|
| 2013 |
Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. Plos One. 8: e59380. PMID 23555026 DOI: 10.1371/Journal.Pone.0059380 |
0.638 |
|
| 2013 |
Allen JE, El-Deiry WS. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin. Oncotarget. 4: 184-91. PMID 23468473 DOI: 10.18632/Oncotarget.883 |
0.563 |
|
| 2013 |
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science Translational Medicine. 5: 171ra17. PMID 23390247 DOI: 10.1126/Scitranslmed.3004828 |
0.725 |
|
| 2013 |
Vasekar M, Allen JE, Joudeh J, Claxton D. Emerging molecular therapies for the treatment of acute lymphoblastic leukemia. Advances in Experimental Medicine and Biology. 779: 341-58. PMID 23288648 DOI: 10.1007/978-1-4614-6176-0_16 |
0.331 |
|
| 2013 |
Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J, El-Deiry WS. Novel antineoplastics targeting genetic changes in colorectal cancer. Advances in Experimental Medicine and Biology. 779: 1-34. PMID 23288633 DOI: 10.1007/978-1-4614-6176-0_1 |
0.568 |
|
| 2013 |
Allen JE, Gallant J, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer Plos One. 8. DOI: 10.1371/Annotation/Aaa12360-0C90-42C3-Bc43-D00022B68B81 |
0.504 |
|
| 2013 |
Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS, Kwak LW, Andreeff M. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas Blood. 122: 3822-3822. DOI: 10.1182/Blood.V122.21.3822.3822 |
0.575 |
|
| 2013 |
Talekar MK, Allen JE, El-Deiry WS. ONC201(TIC10) Induces TRAIL and Cell Death In Preclinical Models Of Pediatric Lymphoma Blood. 122: 1671-1671. DOI: 10.1182/Blood.V122.21.1671.1671 |
0.633 |
|
| 2013 |
Talekar MK, Allen JE, El-Deiry WS. Abstract LB-307: TRAIL-inducing agent -TIC10 and combinatorial therapeutics in pediatric lymphoma: a targeted approach. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-307 |
0.626 |
|
| 2013 |
Prabhu VV, Allen JE, Dicker DT, Ding Y, El-Deiry WS. Abstract 3732: Therapeutic targeting of colorectal cancer stem cells by TRAIL-inducing small molecule TIC10. Cancer Research. 73: 3732-3732. DOI: 10.1158/1538-7445.Am2013-3732 |
0.665 |
|
| 2013 |
Allen JE, Patel AS, Dicker DT, Sheehan JM, Glantz M, El-Deiry WS. Abstract 3483: Modeling circulating tumor cells in the peripheral blood and CSF of breast cancer patients. Cancer Research. 73: 3483-3483. DOI: 10.1158/1538-7445.Am2013-3483 |
0.581 |
|
| 2013 |
Imperato GH, Allen JE, El-Deiry WS. Abstract 2949: Characterization of TIC10, a novel small molecule inducer of TRAIL, in combination with chemotherapy for lymphomain vitro. Cancer Research. 73: 2949-2949. DOI: 10.1158/1538-7445.Am2013-2949 |
0.645 |
|
| 2013 |
Lim B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Abstract 2943: Lapatinib restores TRAIL-mediated apoptosis in TRAIL-resistant Triple Negative Breast Cancer (TNBC) through an off-target strategy that appears to be independent of increased death receptor expression. Cancer Research. 73: 2943-2943. DOI: 10.1158/1538-7445.Am2013-2943 |
0.606 |
|
| 2013 |
Gokare PR, Finnberg N, Allen J, Dai J, El-Deiry W. Abstract 2197: p53-dependent expression of the fluorouracil (5-FU) catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in mouse liver. Cancer Research. 73: 2197-2197. DOI: 10.1158/1538-7445.Am2013-2197 |
0.508 |
|
| 2013 |
Allen JE, El-Deiry WS. Abstract 2059: Kinase library siRNA screen identifies KSR1 as a synergistic therapeutic target in combination with TIC10. Cancer Research. 73: 2059-2059. DOI: 10.1158/1538-7445.Am2013-2059 |
0.567 |
|
| 2013 |
Lim B, Dolloff N, Allen J, Dicker D, El-Deiry W. Abstract P6-02-01: Elucidating the change of TRAIL sensitivity in basal like TNBC cell lines by lapatinib, and further therapeutic implication Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-02-01 |
0.602 |
|
| 2013 |
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... ... Allen J, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182 |
0.368 |
|
| 2013 |
Kaifi J, Kunkel M, Allen J, Dicker D, Das A, Gusani N, Reed M, Kimchi E, Staveley-O'Carroll K, El-Deiry W. Presence of Circulating Tumor Cells in Patients With Resectable Colorectal Cancer Lung Metastases is A Potential Indicator for Extrathoracic Disease Journal of Surgical Research. 179: 285. DOI: 10.1016/J.Jss.2012.10.558 |
0.555 |
|
| 2012 |
Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opinion On Therapeutic Targets. 16: 1161-74. PMID 22998602 DOI: 10.1517/14728222.2012.726985 |
0.573 |
|
| 2012 |
Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Molecular Cancer Therapeutics. 11: 2321-30. PMID 22964485 DOI: 10.1158/1535-7163.Mct-12-0578 |
0.571 |
|
| 2012 |
Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (Georgetown, Tex.). 11: 3312-23. PMID 22895172 DOI: 10.4161/Cc.21670 |
0.592 |
|
| 2012 |
Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biology & Therapy. 13: 1143-51. PMID 22892844 DOI: 10.4161/Cbt.21354 |
0.55 |
|
| 2012 |
Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Molecular Cancer Therapeutics. 11: 2087-95. PMID 22802267 DOI: 10.1158/1535-7163.Mct-12-0366 |
0.546 |
|
| 2012 |
Allen J, Patel A, Dicker D, Sheehan J, Glantz MJ, El-Deiry W. Compartmentalization of tumor cells to the CSF or peripheral blood of a breast cancer patient with CNS metastasis. Journal of Clinical Oncology. 30: e11544-e11544. DOI: 10.1200/Jco.2012.30.15_Suppl.E11544 |
0.557 |
|
| 2012 |
Dolloff NG, Zhou L, Peters K, Navaraj A, Allen J, Das A, Dicker D, El-Deiry W. Abstract 5665: Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells Cancer Research. 72: 5665-5665. DOI: 10.1158/1538-7445.Am2012-5665 |
0.504 |
|
| 2012 |
Allen JE, Patel AS, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. Abstract 5565: Circulating tumor cells in the peripheral blood and cerebrospinal fluid of patients with central nervous system metastases Cancer Research. 72: 5565-5565. DOI: 10.1158/1538-7445.Am2012-5565 |
0.592 |
|
| 2012 |
Das A, Joudeh J, Peters KL, Allen JE, Zheng S, Dicker DT, Yang Z, El-Deiry WS. Abstract 3413: A population of metastatic colorectal cancer (mCRC) patients with radiologically proven liver metastasis and EpCAM expressing primary tumors show low circulating tumor cell counts by Veridex Cellsearch Cancer Research. 72: 3413-3413. DOI: 10.1158/1538-7445.Am2012-3413 |
0.571 |
|
| 2012 |
Cheng H, Hong B, Zhou L, Allen J, Dicker D, El-Deiry W. Abstract 2758: Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of C-Jun N-terminal kinase activation Cancer Research. 72: 2758-2758. DOI: 10.1158/1538-7445.Am2012-2758 |
0.617 |
|
| 2012 |
Das A, Whitcomb TL, Allen JE, Dicker DT, Peters KL, El-Deiry WS. Abstract 2393: Isolation and characterization of circulating tumor cells in a mouse model of colorectal cancer Cancer Research. 72: 2393-2393. DOI: 10.1158/1538-7445.Am2012-2393 |
0.575 |
|
| 2012 |
Allen JE, Krigsfeld G, Patel AS, Wu GS, Dicker DT, El-Deiry WS. Abstract 1935: Potent anti-tumor effects of TIC10 require Foxo3a and TRAIL gene upregulation Cancer Research. 72: 1935-1935. DOI: 10.1158/1538-7445.Am2012-1935 |
0.636 |
|
| 2012 |
Prabhu VV, Hong B, Allen JE, Dicker DT, Navaraj A, Kopelovich L, El-Deiry WS. Abstract 1170: Anti-tumor effects of p53-pathway restoring compound Prodigiosin in colorectal cancer involve effects on apoptotic signaling, angiogenesis and cancer stem cells Cancer Research. 72: 1170-1170. DOI: 10.1158/1538-7445.Am2012-1170 |
0.647 |
|
| 2011 |
Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2: 752-60. PMID 21987585 DOI: 10.18632/Oncotarget.336 |
0.574 |
|
| 2011 |
Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biology & Therapy. 12: 239-51. PMID 21725213 DOI: 10.4161/Cbt.12.3.17034 |
0.607 |
|
| 2011 |
Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biology & Therapy. 12: 229-38. PMID 21725212 DOI: 10.4161/Cbt.12.3.17033 |
0.561 |
|
| 2011 |
Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology. 141: 430-4. PMID 21699898 DOI: 10.1053/J.Gastro.2011.06.026 |
0.59 |
|
| 2011 |
Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2946-7; author reply. PMID 21690466 DOI: 10.1200/Jco.2011.36.6179 |
0.476 |
|
| 2011 |
Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Research. 71: 5265-75. PMID 21646472 DOI: 10.1158/0008-5472.Can-11-1383 |
0.756 |
|
| 2011 |
Gallant J, Wang W, Dolloff NG, Allen JE, El-Deiry WS. Abstract 674: Novel combinatorial quinacrine cancer therapies for advanced colon cancer Cancer Research. 71: 674-674. DOI: 10.1158/1538-7445.Am2011-674 |
0.534 |
|
| 2011 |
Das A, Allen JE, Dicker DT, Peters KL, Joudeh J, El-Deiry WS. Abstract 5248: Quantum dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells Cancer Research. 71: 5248-5248. DOI: 10.1158/1538-7445.Am2011-5248 |
0.544 |
|
| 2011 |
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Wu GS, El-Deiry WS. Abstract 4502: The small molecule TIC10 has potent anticancer efficacy mediated by induction of TRAIL production in normal and tumor cells Cancer Research. 71: 4502-4502. DOI: 10.1158/1538-7445.Am2011-4502 |
0.769 |
|
| 2011 |
Abdulghani J, Allen JE, Dicker DT, Smith CD, Humphreys RC, El-Deiry WS. Abstract 4097: Sorafenib sensitizes solid tumors to TRAIL or TRAIL receptor agonist antibodies Cellular and Molecular Biology. 71: 4097-4097. DOI: 10.1158/1538-7445.Am2011-4097 |
0.506 |
|
| 2011 |
Peters KL, Allen JE, Dicker DT, Das A, Joudeh J, El-Deiry WS. Abstract 3818: CTC profiling: Integration of biomarker analysis with current Veridex CellSearch technology Cancer Research. 71: 3818-3818. DOI: 10.1158/1538-7445.Am2011-3818 |
0.583 |
|
| 2010 |
Allen JE, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports. 6: 212-220. PMID 20890370 DOI: 10.1007/S11888-010-0069-7 |
0.584 |
|
| 2010 |
Allen JE, Patel L, Krigsfeld G, Mayes PA, Wu GS, El-Deiry WS. Abstract 5467: Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines Cancer Research. 70: 5467-5467. DOI: 10.1158/1538-7445.Am10-5467 |
0.747 |
|
| 2010 |
Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer Current Colorectal Cancer Reports. 6: 212-220. DOI: 10.1007/s11888-010-0069-7 |
0.549 |
|
| 2009 |
Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology & Therapy. 8: 2194-205. PMID 19923899 DOI: 10.4161/Cbt.8.22.10450 |
0.541 |
|
| 2009 |
Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes Cancer Biology and Therapy. 8: 2193-2204. DOI: 10.4161/cbt.8.22.10450 |
0.428 |
|
| Show low-probability matches. |